Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Accelerated Approval For Biomarkers? FDA Considers “Limited Context of Use” To Shorten Qualification Process

This article was originally published in RPM Report

Executive Summary

Biomarker qualification is a hot topic for FDA, industry and Congress, based on the premise that better methods to develop and apply novel biomarkers can be the next big step in helping usher in an era of personalized medicine. One common argument is that the current FDA qualification process is too long. FDA is eager to change that perception.

Advertisement

Related Content

Biomarkers: FDA Working To Define 'Reasonably Likely To Predict' Standard
FDA Aspergillosis Biomarker Qualification Highlights New Drug Development Tool Process

Topics

Advertisement
UsernamePublicRestriction

Register

PS079770

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel